Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis

被引：8
|
作者：
Christopher, Karen L. [1 ]
Elner, Victor M. [1 ]
Demirci, Hakan [1 ]
机构：
[1] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48109 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2017年 / 33卷 / 03期
关键词：
B-CELL LYMPHOMA; RITUXIMAB;
D O I：
10.1097/IOP.0000000000000774
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
引用
收藏
页码：E73 / E75
页数：3
相关论文
共 50 条
  • [21] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Saharat Aungsumart
    Saowalak Turongkaravee
    Sitaporn Youngkong
    Metha Apiwattanakul
    Ammarin Thakkinstian
    Usa Chaikledkaew
    BMC Health Services Research, 23
  • [22] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Mansour A. Alharbi
    Fahad Aldosari
    Ahmed Hasan Althobaiti
    Faris M. Abdullah
    Salman Aljarallah
    Nuha M. Alkhawajah
    Miteb Alanazi
    Yazed AlRuthia
    BMC Health Services Research, 23
  • [23] Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
    Garcia, Alexandra
    Dugast, Emilie
    Shah, Sita
    Morille, Jeremy
    Lebrun-Frenay, Christine
    Thouvenot, Eric
    De Seze, Jerome
    Le Page, Emmanuelle
    Vukusic, Sandra
    Maurousset, Aude
    Berger, Eric
    Casez, Olivier
    Labauge, Pierre
    Ruet, Aurelie
    Raposo, Catarina
    Bakdache, Fabien
    Buffels, Regine
    Le Frere, Fabienne
    Nicot, Arnaud
    Wiertlewski, Sandrine
    Gourraud, Pierre-Antoine
    Berthelot, Laureline
    Laplaud, David
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (03):
  • [24] A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Cuker, Adam
    Coles, Alasdair J.
    Sullivan, Herman
    Fox, Edward
    Goldberg, Mark
    Oyuela, Pedro
    Purvis, Annie
    Beardsley, Diana S.
    Margolin, David H.
    BLOOD, 2011, 118 (24) : 6299 - 6305
  • [25] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Alharbi, Mansour A.
    Aldosari, Fahad
    Althobaiti, Ahmed Hasan
    Abdullah, Faris M.
    Aljarallah, Salman
    Alkhawajah, Nuha M.
    Alanazi, Miteb
    AlRuthia, Yazed
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [26] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter A.
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen L.
    LANCET, 2011, 378 (9805) : 1779 - 1787
  • [27] Clinical Pathway for the Diagnosis and Management of Patients With Relapsing-Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population
    Caparo-Zamalloa, Cesar
    Velasquez-Rimachi, Victor
    Mori, Nicanor
    Duenas-Pacheco, Wenzel Ivan
    Huerta-Rosario, Andrely
    Farronay-Garcia, Chandel
    Molina, Roberto A.
    Alva-Diaz, Carlos
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [28] Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents
    Finkelsztejn, Alessandro
    Gabbai, Alberto Alain
    Fragoso, Yara Dadalti
    Carra, Adriana
    Angel Macias-Islas, Miguel
    Arcega-Revilla, Raul
    Garcia-Bonitto, Juan
    Luis Oehninger-Gatti, Carlos
    Orozco-Escobar, Geraldine
    Tarulla, Adriana
    Vergara, Fernando
    Vizcarra, Darwin
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (10) : 799 - 806
  • [29] Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study
    Filippi, Massimo
    Grimaldi, Luigi
    Conte, Antonella
    Totaro, Rocco
    Valente, Maria Rosaria
    Malucchi, Simona
    Granella, Franco
    Cordioli, Cinzia
    Morra, Vincenzo Brescia
    Zanetta, Chiara
    Perini, Daria
    Santoni, Laura
    EASIER Study Working Grp
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 340 - 354
  • [30] Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
    Malin Boremalm
    Peter Sundström
    Jonatan Salzer
    Journal of Neurology, 2021, 268 : 2161 - 2168
12345